SCHEMBL2298534

SCHEMBL2298534

CC(C)(C)[C@](CC(=O)O)(c1ccccc1)n1cnc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 1/20 0.45
CYP2C19 P33261 2/20 0.43
HIF1A Q16665 1/20 0.43
ASAH1 Q13510 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
APAF1 O14727 1/20 0.42
FDPS P14324 1/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
NPC1 O15118 3/20 0.40
LMNA P02545 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RAB9A P51151 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
MAPT P10636 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2295166 0.73 FGFR1 (0.46) CYP2C19HIF1ASMN1; SMN2ALDH1A1HPGD
SCHEMBL11152005 0.72 EGLN3 (0.43) EGLN3ASAH1SMN1; SMN2APAF1FDPS
SCHEMBL10683773 0.72 APAF1 (0.44) EGLN3ASAH1SMN1; SMN2APAF1FDPS
SCHEMBL2164037 0.71 EGLN3 (0.45) EGLN3CYP2C19ASAH1SMN1; SMN2APAF1
SCHEMBL3796582 0.70 SMN1; SMN2 (0.44) EGLN3ASAH1SMN1; SMN2APAF1FDPS
SCHEMBL2794301 0.70 HTT (0.48) EGLN3ASAH1SMN1; SMN2HPGDLMNA
SCHEMBL6175276 0.70 FDPS (0.46) EGLN3SMN1; SMN2APAF1FDPSHPGD
SCHEMBL2614317 0.69 NPC1 (0.49) SMN1; SMN2FDPSKDM4EALDH1A1HPGD
SCHEMBL14268957 0.69 ALDH1A1 (0.47) EGLN3CYP2C19ASAH1APAF1FDPS
SCHEMBL6174967 0.68 FDPS (0.46) EGLN3ASAH1SMN1; SMN2APAF1FDPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003806-B2 Integrin antagonists useful as anticancer agents OSI Pharmaceuticals, LLC (US) 2011-08-23 US disclosed